SAB Biotherapeutics (SABS) Operating Income: 2021-2025
Historic Operating Income for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$12.7 million.
- SAB Biotherapeutics' Operating Income fell 12.11% to -$12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.2 million, marking a year-over-year increase of 16.58%. This contributed to the annual value of -$42.9 million for FY2024, which is 12.70% down from last year.
- According to the latest figures from Q3 2025, SAB Biotherapeutics' Operating Income is -$12.7 million, which was down 30.28% from -$9.7 million recorded in Q2 2025.
- Over the past 5 years, SAB Biotherapeutics' Operating Income peaked at $813,924 during Q1 2021, and registered a low of -$18.9 million during Q4 2023.
- For the 3-year period, SAB Biotherapeutics' Operating Income averaged around -$10.4 million, with its median value being -$10.2 million (2024).
- In the last 5 years, SAB Biotherapeutics' Operating Income crashed by 924.07% in 2022 and then soared by 46.97% in 2024.
- Quarterly analysis of 5 years shows SAB Biotherapeutics' Operating Income stood at -$7.3 million in 2021, then decreased by 7.02% to -$7.9 million in 2022, then slumped by 140.12% to -$18.9 million in 2023, then spiked by 46.97% to -$10.0 million in 2024, then decreased by 12.11% to -$12.7 million in 2025.
- Its last three reported values are -$12.7 million in Q3 2025, -$9.7 million for Q2 2025, and -$10.8 million during Q1 2025.